# OnCo record nct02773030 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct02773030/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct02773030", "NCT02773030" ;
  schema:name "A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple"@en ;
  schema:description "A phase 1/2 trial of Iberdomide, Dexamethasone, Daratumumab in multiple myeloma, run by Celgene, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct02773030/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02773030> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2016-10-14" ;
  onco:cancers <https://onco.cc/cancers/multiple-myeloma/> ;
  onco:technologies <https://onco.cc/technologies/celmods/>, <https://onco.cc/technologies/protac-degrader/> ;
  onco:drugs <https://onco.cc/drugs/iberdomide/>, <https://onco.cc/drugs/dexamethasone/>, <https://onco.cc/drugs/daratumumab/>, <https://onco.cc/drugs/bortezomib/>, <https://onco.cc/drugs/carfilzomib/> ;
  onco:companies <https://onco.cc/companies/bms/> .